enGene Holdings Inc.
News
enGene Holdings GAAP EPS of -$0.32 beats by $0.07
SeekingAlpha.com: All News enGene Holdings reports Q3 2024 financial results with a GAAP EPS beating estimates by $0.07.\n more…
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update
Business Wire enGene Holdings Inc. (Nasdaq: ENGN, or enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as...\n more…
Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Price Target at $34.40
Ticker Report enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned an average rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Seven investment...\n more…
enGene to Participate in Upcoming Investor Conferences
Business Wire enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and...\n more…
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Business Wire enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for...\n more…
enGene Announces Appointment of Ron Cooper as Chief Executive Officer
Business Wire enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for...\n more…